XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue by Sales Category | The following tables provide detail by sales category:
|  | Three Months Ended June 30, 2025 |  | Three Months Ended June 30, 2024
(in millions) |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total
Established Pharmaceutical Products — |  |  |  |  |  |  |  |  |  |  |  |
Key Emerging Markets |  | $ | — |  |  | $ | 1,059 |  |  | $ | 1,059 |  |  | $ | — |  |  | $ | 988 |  |  | $ | 988 |
Other |  | — |  |  | 324 |  |  | 324 |  |  | — |  |  | 306 |  |  | 306 |
Total |  | — |  |  | 1,383 |  |  | 1,383 |  |  | — |  |  | 1,294 |  |  | 1,294 |
Nutritional Products — |  |  |  |  |  |  |  |  |  |  |  |
Pediatric Nutritionals |  | 587 |  |  | 467 |  |  | 1,054 |  |  | 564 |  |  | 495 |  |  | 1,059 |
Adult Nutritionals |  | 370 |  |  | 788 |  |  | 1,158 |  |  | 369 |  |  | 722 |  |  | 1,091 |
Total |  | 957 |  |  | 1,255 |  |  | 2,212 |  |  | 933 |  |  | 1,217 |  |  | 2,150 |
Diagnostic Products — |  |  |  |  |  |  |  |  |  |  |  |
Core Laboratory |  | 351 |  |  | 1,007 |  |  | 1,358 |  |  | 327 |  |  | 1,002 |  |  | 1,329 |
Molecular |  | 35 |  |  | 88 |  |  | 123 |  |  | 33 |  |  | 94 |  |  | 127 |
Point of Care |  | 104 |  |  | 44 |  |  | 148 |  |  | 107 |  |  | 49 |  |  | 156 |
Rapid Diagnostics |  | 321 |  |  | 223 |  |  | 544 |  |  | 345 |  |  | 238 |  |  | 583 |
Total |  | 811 |  |  | 1,362 |  |  | 2,173 |  |  | 812 |  |  | 1,383 |  |  | 2,195 |
Medical Devices — |  |  |  |  |  |  |  |  |  |  |  |
Rhythm Management |  | 340 |  |  | 333 |  |  | 673 |  |  | 292 |  |  | 315 |  |  | 607 |
Electrophysiology |  | 322 |  |  | 378 |  |  | 700 |  |  | 287 |  |  | 340 |  |  | 627 |
Heart Failure |  | 282 |  |  | 86 |  |  | 368 |  |  | 244 |  |  | 77 |  |  | 321 |
Vascular |  | 283 |  |  | 474 |  |  | 757 |  |  | 275 |  |  | 449 |  |  | 724 |
Structural Heart |  | 289 |  |  | 347 |  |  | 636 |  |  | 258 |  |  | 306 |  |  | 564 |
Neuromodulation |  | 193 |  |  | 61 |  |  | 254 |  |  | 192 |  |  | 51 |  |  | 243 |
Diabetes Care |  | 794 |  |  | 1,187 |  |  | 1,981 |  |  | 637 |  |  | 1,011 |  |  | 1,648 |
Total |  | 2,503 |  |  | 2,866 |  |  | 5,369 |  |  | 2,185 |  |  | 2,549 |  |  | 4,734 |
Other |  | 5 |  |  | — |  |  | 5 |  |  | 4 |  |  | — |  |  | 4 |
Total |  | $ | 4,276 |  |  | $ | 6,866 |  |  | $ | 11,142 |  |  | $ | 3,934 |  |  | $ | 6,443 |  |  | $ | 10,377 |
|  | Six Months Ended June 30, 2025 |  | Six Months Ended June 30, 2024
(in millions) |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total
Established Pharmaceutical Products — |  |  |  |  |  |  |  |  |  |  |  |
Key Emerging Markets |  | $ | — |  |  | $ | 2,024 |  |  | $ | 2,024 |  |  | $ | — |  |  | $ | 1,916 |  |  | $ | 1,916 |
Other |  | — |  |  | 619 |  |  | 619 |  |  | — |  |  | 604 |  |  | 604 |
Total |  | — |  |  | 2,643 |  |  | 2,643 |  |  | — |  |  | 2,520 |  |  | 2,520 |
Nutritional Products — |  |  |  |  |  |  |  |  |  |  |  |
Pediatric Nutritionals |  | 1,175 |  |  | 920 |  |  | 2,095 |  |  | 1,078 |  |  | 990 |  |  | 2,068 |
Adult Nutritionals |  | 737 |  |  | 1,526 |  |  | 2,263 |  |  | 733 |  |  | 1,417 |  |  | 2,150 |
Total |  | 1,912 |  |  | 2,446 |  |  | 4,358 |  |  | 1,811 |  |  | 2,407 |  |  | 4,218 |
Diagnostic Products — |  |  |  |  |  |  |  |  |  |  |  |
Core Laboratory |  | 683 |  |  | 1,852 |  |  | 2,535 |  |  | 637 |  |  | 1,897 |  |  | 2,534 |
Molecular |  | 75 |  |  | 170 |  |  | 245 |  |  | 75 |  |  | 181 |  |  | 256 |
Point of Care |  | 204 |  |  | 86 |  |  | 290 |  |  | 205 |  |  | 90 |  |  | 295 |
Rapid Diagnostics |  | 720 |  |  | 437 |  |  | 1,157 |  |  | 826 |  |  | 498 |  |  | 1,324 |
Total |  | 1,682 |  |  | 2,545 |  |  | 4,227 |  |  | 1,743 |  |  | 2,666 |  |  | 4,409 |
Medical Devices — |  |  |  |  |  |  |  |  |  |  |  |
Rhythm Management |  | 644 |  |  | 614 |  |  | 1,258 |  |  | 563 |  |  | 606 |  |  | 1,169 |
Electrophysiology |  | 621 |  |  | 708 |  |  | 1,329 |  |  | 556 |  |  | 658 |  |  | 1,214 |
Heart Failure |  | 544 |  |  | 163 |  |  | 707 |  |  | 481 |  |  | 145 |  |  | 626 |
Vascular |  | 551 |  |  | 916 |  |  | 1,467 |  |  | 529 |  |  | 884 |  |  | 1,413 |
Structural Heart |  | 571 |  |  | 642 |  |  | 1,213 |  |  | 491 |  |  | 588 |  |  | 1,079 |
Neuromodulation |  | 369 |  |  | 113 |  |  | 482 |  |  | 373 |  |  | 96 |  |  | 469 |
Diabetes Care |  | 1,542 |  |  | 2,266 |  |  | 3,808 |  |  | 1,226 |  |  | 1,991 |  |  | 3,217 |
Total |  | 4,842 |  |  | 5,422 |  |  | 10,264 |  |  | 4,219 |  |  | 4,968 |  |  | 9,187 |
Other |  | 8 |  |  | — |  |  | 8 |  |  | 7 |  |  | — |  |  | 7 |
Total |  | $ | 8,444 |  |  | $ | 13,056 |  |  | $ | 21,500 |  |  | $ | 7,780 |  |  | $ | 12,561 |  |  | $ | 20,341 |
Schedule of Changes in Contract Liabilities | Changes in the contract liabilities during the period are as follows:
(in millions) |  |
Contract Liabilities: |  |
Balance at December 31, 2024 |  | $ | 568 |
Unearned revenue from cash received during the period |  | 252 |
Revenue recognized related to contract liability balance |  | (192) |
Balance at June 30, 2025 |  | $ | 628 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration